Based on the results of network pharmacology analysis, PIK3CA, EGFR, TP53, MAPK1, and MAPK3 were identified as key targets of FZP in HCC treatment, which was verified using western blotting. This evidence concerns the gene MAPK1 and hepatocellular carcinoma.